Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Leukemia: early-phase trial registry
51 of 274 indexed Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #35 of 28,707 conditions by registered trial count.
274 US clinical trials · 51 currently recruiting · #35 of 28,707 conditions by registered trial count
Leukemia: 274 US clinical trials tracked, 51 recruiting.
Leukemia is the subject of 274 registered US clinical trials on ClinicalTrials.gov, 51 of them currently open to new participants. 19 are in Phase 3-4 (later-stage) and 193 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 37 of these trials.
Enrollment posture brief
Registry condition leukemia
OPEN 51 | RECR 19% | LATE 19 | EARLY 193 | RANK #35 | SPON 37
Volume-matched condition peers
Nearest open-share peer: Rheumatoid Arthritis (19% recruiting · 199 trials)
Leukemia lists 51 open slots (19% of 274 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Leukemia is recruiting below its size-band peers.
51 of 274 indexed trials (18.6%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Leukemia trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 37 of 274 trials (13.5%). 84 distinct sponsors appear on at least one study for this condition label.
-
Most Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 49 among the 234 trials that report a genuine target (sentinel values excluded). 170 of those (72.6%) plan for fewer than 100 participants.
-
Leukemia research is mostly interventional.
243 interventional and 31 observational studies make up this index (88.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
274 total, page 5 of 6
Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders
Fred Hutchinson Cancer Center
NCT00002792
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
NCT01490723
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)
M.D. Anderson Cancer Center
NCT00364286
Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation
Stanford University
NCT05282459
Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation
M.D. Anderson Cancer Center
NCT02196857
Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias
M.D. Anderson Cancer Center
NCT01396499
Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia
Northwestern University
NCT00005619
Allogeneic Transplantation From Related Haploidentical Donors
Stanford University
NCT00185692
Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT00004263
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
OHSU Knight Cancer Institute
NCT00053248
Sirolimus in Combination With MEC in High Risk Myeloid Leukemias
Abramson Cancer Center at Penn Medicine
NCT00780104
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
NCT00402558
Concurrent School Attendance And Cancer Therapy: The Experiences of 6-12 Year Old Pediatric Oncology Patients
St. Jude Children's Research Hospital
NCT01383473
Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
NCT00002832
Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia
Washington University School of Medicine
NCT00008697
Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab
Memorial Sloan Kettering Cancer Center
NCT01416974
Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
NCT00526292
Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia
Children's Oncology Group
NCT00003735
8-Chloro-Adenosine in Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT00714103
Evaluating the Use of RFT5-dgA to Deplete Alloreactive Cells Prior to Haploidentical Stem Cell Transplantation
Baylor College of Medicine
NCT00586547
Use of Topotecan in Patients With Refractory Acute Leukemia
US Department of Veterans Affairs
NCT00100477
Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia
City of Hope Medical Center
NCT00686218
Interferon Alfa in Treating Children With HIV-Related Cancer
Children's Oncology Group
NCT00002621
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
University of California, San Francisco
NCT00301951
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
M.D. Anderson Cancer Center
NCT00005092
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
Pharmacyclics
NCT01149668
Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG
M.D. Anderson Cancer Center
NCT01390402
Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation
Baylor College of Medicine
NCT00057005
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
University of California, San Francisco
NCT00304018
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy
Dana-Farber Cancer Institute
NCT00005988
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
Roswell Park Cancer Institute
NCT00003661
Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Dana-Farber Cancer Institute
NCT00301093
Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia
Case Comprehensive Cancer Center
NCT00021151
Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome
Memorial Sloan Kettering Cancer Center
NCT00003959
Photodynamic Therapy in Treating Patients With Lymphoma or Chronic Lymphocytic Leukemia
Roswell Park Cancer Institute
NCT00054171
Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria
Jonsson Comprehensive Cancer Center
NCT00112983
Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Memorial Sloan Kettering Cancer Center
NCT00045422
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer
Memorial Sloan Kettering Cancer Center
NCT00014469
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
Drexel University College of Medicine
NCT00003619
Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus
Boston Medical Center
NCT00006340
Vaccine Therapy in Preventing Flu in Children With Acute Lymphoblastic Leukemia
Roswell Park Cancer Institute
NCT00022035
Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia
Fred Hutchinson Cancer Center
NCT00005948
Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia
Virginia Commonwealth University
NCT00017342
Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Northwestern University
NCT00004896
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
Jonsson Comprehensive Cancer Center
NCT00100997
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
Memorial Sloan Kettering Cancer Center
NCT00002502
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia
Herbert Irving Comprehensive Cancer Center
NCT00008190
R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia
University of Maryland, Baltimore
NCT00004009
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
National Cancer Institute (NCI)
NCT00019656
UCN-01 in Treating Patients With Advanced Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00003289
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 98 |
| Phase 2 | 95 |
| Phase 3 | 18 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Leukemia page
274 registered trials, 51 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 51 Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Leukemia trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Leukemia condition card totals 274 registered trials; most-linked intervention cyclophosphamide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.